Edition:
United Kingdom

Amgen Inc (AMGN.O)

AMGN.O on Nasdaq

178.30USD
24 Apr 2019
Change (% chg)

$-1.46 (-0.81%)
Prev Close
$179.76
Open
$180.14
Day's High
$180.83
Day's Low
$178.26
Volume
2,711,618
Avg. Vol
3,078,324
52-wk High
$210.19
52-wk Low
$165.22

About

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN... (more)

Overall

Beta: 1.40
Market Cap(Mil.): $135,588.20
Shares Outstanding(Mil.): 729.67
Dividend: 1.15
Yield (%): 2.48

Financials

  AMGN.O Industry Sector
P/E (TTM): 16.90 29.30 32.55
EPS (TTM): 11.00 -- --
ROI: 11.98 14.23 13.83
ROE: 26.43 15.46 15.25

Novartis shares rise as Swiss drugmaker lifts 2019 profit outlook

ZURICH Swiss drugmaker Novartis raised its 2019 profit target on Wednesday, striking an upbeat tone over a legal fight with peer and partner Amgen and on the safety of a key gene therapy that could win approval next month.

24 Apr 2019

Novartis shares rise as Swiss drugmaker lifts 2019 profit outlook

ZURICH Swiss drugmaker Novartis raised its 2019 profit target on Wednesday, striking an upbeat tone over a legal fight with peer and partner Amgen and on the safety of a key gene therapy that could win approval next month.

24 Apr 2019

UPDATE 2-Novartis shares rise as Swiss drugmaker lifts 2019 profit outlook

* Says "business as usual" for migraine drug despite court case

24 Apr 2019

BRIEF-Novartis CEO Says Zolgensma "on track" as May approval date approaches

* CEO SAYS APPROVAL OF ZOLGENSMA GENE THERAPY "ON TRACK" FOR MAY, TAKING ICER REVIEW INTO ACCOUNT WHEN DECIDING ON PRICE

24 Apr 2019

Amgen sets $21,900 annual price for new Evenity bone drug

Amgen Inc on Monday set the U.S. list price for its new Evenity osteoporosis drug at $1,825 a month, or $21,900 for a full 12-month course of injections.

15 Apr 2019

Amgen sets $21,900 annual price for new Evenity bone drug

April 15 Amgen Inc on Monday set the U.S. list price for its new Evenity osteoporosis drug at $1,825 a month, or $21,900 for a full 12-month course of injections.

15 Apr 2019

Amgen's postmenopausal osteoporosis drug gets FDA greenlight

The U.S. Food and Drug Administration said on Tuesday it had approved Amgen Inc's osteoporosis treatment for postmenopausal women who are at high risk of fracture.

09 Apr 2019

UPDATE 2-Amgen's postmenopausal osteoporosis drug gets FDA greenlight

April 9 The U.S. Food and Drug Administration said on Tuesday it had approved Amgen Inc's osteoporosis treatment for postmenopausal women who are at high risk of fracture.

09 Apr 2019

Amgen's postmenopausal osteoporosis drug gets FDA approval

April 9 The U.S. Food and Drug Administration on Tuesday approved Amgen Inc's osteoporosis treatment for postmenopausal women at high risk for fracture, according to the regulator's website.

09 Apr 2019

Novartis, Amgen in dispute over migraine drug partnership

NEW YORK/LOS ANGELES Swiss drugmaker Novartis AG sued Amgen Inc on Thursday, accusing the U.S. biotechnology company of trying to wrongfully back out of agreements to jointly develop and market the migraine prevention drug Aimovig and keep the profits for itself.

04 Apr 2019

Earnings vs. Estimates